Opinion|Videos|September 3, 2025
Highlighting Deuruxolitinib for Alopecia Areata
Key Takeaways
- Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
- Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
Panelists discuss how deuruxolitinib, evaluated in the THRIVE-AA1 and THRIVE-AA2 phase 3 trials, differs from previous Janus kinase (JAK) inhibitors in its formulation and efficacy, and why ensuring long-term patient adherence through 24 weeks is crucial for treatment durability and success.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Mostaghimi: Deuruxolitinib has been evaluated in the
THRIVE-AA1 andTHRIVE-AA2 multinational phase 3 clinical trials gaining FDA approval in 2024. How did this JAK inhibitor differ from the last past two 2 JAK inhibitors approved in the previous 2 years?- Durability is often an issue seen in studies where patients don’t remain on therapies long-term. Why is it so important to see the majority of patients staying on deuruxolitinib through 24 weeks?
- How does the durability of the different JAK inhibitors compare?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Consequences If ACA Premium Subsidies End in 2026
2
Stereotactic Body Radiation Therapy Equally Effective as Surgery in Stage I NSCLC
3
New PBM Laws Seek to Protect Independent Pharmacies but Could Raise Costs, Limit Patient Access
4
Measles Outbreaks Cause Financial, Public Health Burden in US
5
